Sanofi launches new in­sulin Tou­jeo in In­dia

BioSpectrum (India) - - COMPANY NEWS -

Sanofi In­dia con­tin­ues to de­liver break­through medicines for the man­age­ment of di­a­betes with the launch of its new prod­uct - Tou­jeo, the next gen­er­a­tion basal in­sulin. Tou­jeo is a on­cedaily, long-act­ing basal ana­log in­sulin that im­proves glycemic con­trol in adults with type 1 and type 2 di­a­betes. Low blood sugar, or hy­po­glycemia is a con­stant fear amongst peo­ple on in­sulin. Tou­jeo has demon­strated that it ef­fec­tively low­ers blood glu­cose, while min­i­miz­ing the risk of hy­po­glycemia. It works by slowly re­leas­ing small amounts of in­sulin to pro­vide con­tin­u­ous glu­cose-low­er­ing ac­tiv­ity that lasts be­yond 24 hours. With its sta­ble and flat/peak-less ac­tion pro­file, Tou­jeo re­duces glycemic vari­abil­ity, i.e. the daily highs and lows that peo­ple with di­a­betes on in­sulin may ex­pe­ri­ence. The prod­uct also comes with an im­pres­sive MY COACH pa­tient sup­port pro­gram (of­fered free to pa­tients pre­scribed Tou­jeo). This pa­tient sup­port pro­gram pro­vides six com­pre­hen­sive months of hand-hold­ing pa­tients through their treat­ment jour­ney - tips on diet and life­style, train­ing on in­jec­tion tech­niques, sugar mon­i­tor­ing and more, via a mix of tele­phonic and in-per­son ses­sions. MY COACH will be of­fered un­der Sanofi’s Saath-7 ini­tia­tive, the long­est run­ning pa­tient sup­port pro­gram in In­dia, which has ser­viced more than 4,12,000 peo­ple with di­a­betes on in­sulin till date.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.